Nexalin Technology (NASDAQ:NXL) Announces Earnings Results

Nexalin Technology (NASDAQ:NXL) posted its quarterly earnings data on Friday. The company reported ($0.13) earnings per share (EPS) for the quarter, Zacks reports. Nexalin Technology had a negative return on equity of 209.20% and a negative net margin of 5,057.14%.

Nexalin Technology Stock Down 7.7%

NXL traded down $0.09 during trading on Friday, reaching $1.08. The company’s stock had a trading volume of 243,837 shares, compared to its average volume of 474,632. The company has a market cap of $19.06 million, a price-to-earnings ratio of -1.42 and a beta of 3.63. The firm has a fifty day simple moving average of $1.19 and a two-hundred day simple moving average of $1.13. Nexalin Technology has a 1 year low of $0.70 and a 1 year high of $4.49.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Wall Street Zen raised Nexalin Technology to a “hold” rating in a report on Saturday, November 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nexalin Technology in a research report on Tuesday. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $5.00.

Nexalin Technology Company Profile

Nexalin Technology, Inc, a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia.